Faron’s Traumakine Flops In Phase III
Faron Pharmaceuticals’ stock has plummeted more than 80% on the news its lead drug failed in a Phase III trial – the company will now shift its focus to an investigational cancer therapy, but this is yet to enter the clinic.
You may also be interested in...
Coronavirus Update: Drug Shortages On Horizon, Firms Offer Medical Staff For The Fight, More Studies Start
Fears over shortages of drugs needed for ventilated patients rise, while Merck & Co, Pfizer and Lilly allow their medics to volunteer, and attention turns to beta-interferon products and NK cell therapies to fight the virus.
After a major setback to its lead asset last year, Faron looks to novel immunotherapy
A selection of articles you might have missed from April 2022, including exclusive interviews, an in depth look at the impact of COVID-19 on clinical trial trends, and the latest Rising Leaders series.